Lesson
Start with the Clinical Pattern
Autoimmune disease involves immune responses against the body. Symptoms and organ involvement determine the evaluation; a laboratory label alone does not establish the diagnosis.
- Organ involvement
- Clinical probability
- Alternative explanations
What explains the clinical pattern?
What is happening now?
What risks accompany this treatment?
Recognize a pattern
Persistent inflammatory joint symptoms, a characteristic rash, or a defined organ disorder warrants a different investigation from isolated fatigue. Autoimmune illnesses vary in presentation and course. Infection and other disorders can produce similar symptoms; history, examination and directed testing must be interpreted together.
Choose a question before a test
Separate three tasks: identifying the disease, measuring current activity, and checking treatment safety. The same patient may need evidence for all three, but one abnormal result rarely answers them all. Record the reason for ordering each test and the decision that its result could change.
Match treatment to the disease
An autoimmune mechanism does not imply that every patient needs systemic immunosuppression. Celiac disease is treated principally through strict gluten avoidance, with nutritional support and follow-up. Hypothyroidism from Hashimoto disease is treated with thyroid hormone replacement; patients without hypothyroidism may instead need surveillance. Other diseases require immune-directed therapy selected for their severity and organ involvement. Use the disease-specific module for the treatment regimen.
Quick check
Checking for saved practice…
Lesson
ESR and CRP: Evidence of Inflammation
Inflammation markers can support assessment and follow-up, but they do not identify a specific autoimmune disease.
- Erythrocyte sedimentation rate
- C-reactive protein
- Clinical context
Red-cell sedimentation
Inflammatory protein
History, examination and test context
Understand the measurement
ESR describes how rapidly red cells settle under specified laboratory conditions. CRP is a liver-produced protein that increases with inflammation. Neither test identifies an autoantibody. Infection and noninfectious inflammation can both elevate these markers.
Interpret limitations
ESR is affected by factors including age, pregnancy and blood-cell characteristics. CRP does not locate inflammation or name its cause. Use the reporting laboratory reference range and units. An elevated marker supports further evaluation; it does not establish rheumatoid arthritis, lupus, or a need for a higher immunosuppressant dose.
Quick check
Checking for saved practice…
Lesson
ANA and Rheumatoid Factor: Context Matters
ANA and rheumatoid factor are autoantibody tests. They are not interchangeable with ESR or CRP and cannot independently establish an autoimmune diagnosis.
- Antinuclear antibodies
- Rheumatoid factor
- Positive and negative results
Nuclear targets; positivity is not a lupus diagnosis
IgG target; negativity does not exclude RA
Use findings together, not an isolated result
Interpret ANA carefully
ANA detects antibodies directed against nuclear targets. A positive result can occur in healthy people and in several illnesses or with certain medications. Interpret the assay, titer or reported result alongside symptoms. Positivity alone does not justify treating lupus. A negative ANA reduces the likelihood of lupus in the appropriate setting; it does not exclude every autoimmune disorder.
Interpret RF carefully
Rheumatoid factor is an autoantibody directed against immunoglobulin G. It may be present in rheumatoid arthritis, other conditions or people without rheumatoid arthritis. Conversely, rheumatoid arthritis can occur with a negative RF. Persistent inflammatory joint findings require clinical evaluation regardless of whether RF is positive or negative.
Quick check
Checking for saved practice…
Lesson
Screening Before Immune Therapy
Infection prevention depends on the proposed treatment, infection history, exposures and disease context. Screening and prophylaxis are separate decisions.
- Latent tuberculosis
- Hepatitis status
- Treatment-specific planning
Identify drug, exposures and infection history
Interpret the relevant screening results
Coordinate prevention, treatment or monitoring
Use a risk-based plan
EULAR recommends latent TB screening before biologic and targeted synthetic DMARDs; it can also be considered with other antirheumatic treatments. This is not one identical requirement for every immune-modifying drug. Follow the specific product label and regional guidance. A screening result is the beginning of an evaluation and prevention plan, not proof that all future infection risk is eliminated.
Distinguish hepatitis decisions
Establish hepatitis B status before relevant antirheumatic therapy and select monitoring or antiviral prevention from that status and the treatment risk. Hepatitis C RNA positivity warrants referral for antiviral treatment. Do not describe hepatitis B and C as having identical reactivation pathways or automatically prescribe the same prophylaxis for both.
Apply actual label requirements
Before adalimumab, evaluate for latent TB and arrange treatment when indicated; continue infection surveillance even after a negative initial test. Rituximab requires HBsAg and anti-HBc testing before treatment. Evidence of current or prior HBV infection calls for specialist prevention and monitoring planning. A negative HBsAg alone does not close that assessment.
Quick check
Checking for saved practice…
Lesson
Vaccines and Treatment Timing
Assess vaccine type and immune status before treatment. Live and non-live products raise different concerns.
- Live vaccines
- Non-live vaccines
- Corticosteroid exposure
Live or non-live?
Which agents, doses and duration?
Use vaccine-specific and therapy-specific guidance
Separate safety from response
Live vaccines are generally avoided during substantial immunosuppression. Non-live vaccines do not contain replicating vaccine organisms, but the immune response can be reduced. Review indicated vaccines early and plan timing around the therapy where feasible.
Apply the steroid threshold correctly
For live-virus vaccine decisions, CDC considers prednisone-equivalent doses of at least 2 mg/kg/day, or at least 20 mg/day in people weighing more than 10 kg, for at least 14 consecutive days to be high-dose exposure. Live vaccination is deferred for at least one month after stopping such treatment. This is not a universal threshold for every infection risk or adrenal-suppression decision. Short courses, physiologic replacement, and inhaled or topical treatment alone usually do not impose the same restriction.
Quick check
Checking for saved practice…
Lesson
Turn Results into a Follow-Up Plan
Ongoing care needs a plan for disease response, treatment toxicity and new infection concerns. Normal screening results do not make later symptoms irrelevant.
- Clinical response
- Safety monitoring
- Patient communication
Symptoms, function and disease-specific findings
Regimen-specific checks and new symptoms
Disease, toxicity and infection remain distinct possibilities
Monitor distinct outcomes
Ask separately whether the disease is improving and whether treatment is causing harm. Choose laboratory and clinical monitoring from the actual medicine and affected organs. A CBC cannot by itself exclude every infection or detect every treatment toxicity; an antibody result is not a universal treatment target.
Avoid a false choice
A new symptom during treatment can reflect the underlying disease, an adverse drug effect, infection or another condition. Do not automatically label it a flare and escalate immunosuppression. Review the symptom timeline, exposures, medication changes and urgency with the treating team. Treatment interruption and resumption should follow the clinical assessment and the specific regimen.
Discuss malignancy risk specifically
Adalimumab carries malignancy warnings, including lymphoma, and its label calls for examination for nonmelanoma skin cancer before and during therapy. Discuss personal cancer history and the proposed regimen. Do not assign one cancer-risk estimate to all immune therapies or attribute every cancer solely to a medication; the underlying disease and previous or combined treatments also matter.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 19 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- MedlinePlus: autoimmune diseases
- MedlinePlus: ESR
- MedlinePlus: CRP
- American College of Rheumatology: ANA
- MedlinePlus: rheumatoid factor
- EULAR infection screening and prophylaxis recommendations
- CDC: altered immunocompetence
- NIDDK: celiac disease treatment
- NIDDK: Hashimoto disease
- Humira prescribing information: infection and malignancy warnings
- Rituxan prescribing information: HBV assessment